Division of Pharmacology, LACDR, Leiden University, Leiden, the Netherlands.
Clin Pharmacokinet. 2012 Feb 1;51(2):105-17. doi: 10.2165/11595640-000000000-00000.
During the newborn period and early infancy, renal function matures, resulting in changes in the glomerular filtration rate (GFR). This study was performed to quantify developmental changes in the GFR in (pre)term neonates by use of amikacin clearance as proof of concept. The model was used to derive a rational dosing regimen in comparison with currently used dosing regimens for amikacin.
Population pharmacokinetic modelling was performed in nonlinear mixed-effect modelling software (NONMEM version 6.2) using data from 874 neonates obtained from two previously published datasets (gestational age 24-43 weeks; postnatal age 1-30 days; birthweight 385-4650 g). The influence of different age-related, weight-related and other covariates was investigated. The model was validated both internally and externally.
Postmenstrual age was identified as the most significant covariate on clearance. However, the combination of birthweight and postnatal age proved to be superior to postmenstrual age alone. Birthweight was best described using an allometric function with an exponent of 1.34. Postnatal age was identified using a linear function with a slope of 0.2, while co-administration of ibuprofen proved to be a third covariate. Current bodyweight was the most important covariate for the volume of distribution, using an allometric function. The external evaluation supported the prediction of the final pharmacokinetic model. This analysis illustrated clearly that the currently used dosing regimens for amikacin in reference handbooks may possibly increase the risk of toxicities and should be revised. Consequently, a new model-based dosing regimen based on current bodyweight and postnatal age was derived.
Amikacin clearance, reflecting the GFR in neonates, can be predicted by birthweight representing the antenatal state of maturation of the kidney, postnatal age representing postnatal maturation, and co-administration of ibuprofen. Finally, the model reflects maturation of the GFR, allowing for adjustments of dosing regimens for other renally excreted drugs in preterm and term neonates.
在新生儿期和婴儿早期,肾功能逐渐成熟,肾小球滤过率(GFR)发生变化。本研究旨在通过氨基糖苷类药物清除率来量化(早产)新生儿 GFR 的发育变化,以此作为概念验证。该模型用于推导与目前氨基糖苷类药物使用剂量方案相比更为合理的剂量方案。
采用非线性混合效应模型软件(NONMEM 版本 6.2)进行群体药代动力学建模,使用来自先前发表的两项研究数据(胎龄 24-43 周;生后年龄 1-30 天;出生体重 385-4650g)。研究考察了不同年龄相关、体重相关和其他协变量的影响。对模型进行了内部和外部验证。
胎龄是清除率的最显著协变量。然而,出生体重和生后年龄的组合证明优于胎龄单独使用。出生体重最好用指数为 1.34 的幂函数来描述。生后年龄采用斜率为 0.2 的线性函数来描述,而布洛芬的联合给药被确定为第三个协变量。当前体重是分布容积最重要的协变量,采用幂函数。外部评价支持最终药代动力学模型的预测。该分析清楚地表明,目前参考手册中氨基糖苷类药物的剂量方案可能会增加毒性风险,需要进行修订。因此,基于当前体重和生后年龄,提出了一种新的基于模型的剂量方案。
氨基糖苷类药物清除率反映了新生儿的 GFR,可以通过代表肾脏产前成熟度的出生体重、代表产后成熟度的生后年龄以及布洛芬的联合给药来预测。最终,该模型反映了 GFR 的成熟度,可用于调整其他在早产儿和足月儿中经肾脏排泄的药物的剂量方案。